Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Gains from Investment Securities (2019 - 2024)

Historic Gains from Investment Securities for Madrigal Pharmaceuticals (MDGL) over the last 11 years, with Q4 2024 value amounting to $162000.0.

  • Madrigal Pharmaceuticals' Gains from Investment Securities changed N/A to $162000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 5243.2%. This contributed to the annual value of $1.3 million for FY2024, which is 1830.47% down from last year.
  • As of Q4 2024, Madrigal Pharmaceuticals' Gains from Investment Securities stood at $162000.0.
  • In the past 5 years, Madrigal Pharmaceuticals' Gains from Investment Securities registered a high of $1.6 million during Q3 2023, and its lowest value of $162000.0 during Q4 2024.
  • Over the past 3 years, Madrigal Pharmaceuticals' median Gains from Investment Securities value was $809500.0 (recorded in 2020), while the average stood at $852250.0.
  • Within the past 5 years, the most significant YoY rise in Madrigal Pharmaceuticals' Gains from Investment Securities was 2825.55% (2024), while the steepest drop was 2825.55% (2024).
  • Madrigal Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $451000.0 in 2020, then skyrocketed by 260.98% to $1.6 million in 2023, then crashed by 90.05% to $162000.0 in 2024.
  • Its Gains from Investment Securities was $162000.0 in Q4 2024, compared to $1.2 million in Q3 2024 and $1.6 million in Q3 2023.